发布日期:2024-12-30 浏览次数:次
Pirtobrutinib tablet is an oral kinase inhibitor, and more specifically, it is a non-covalent (reversible) BTK inhibitor.
Pirtobrutinib's mechanism of action is that it blocks BTK, which is a signaling protein found across numerous B-cell leukemia and lymphomas, including MCL, CLL, and SLL, that, when stimulated, activates pathways responsible for B-cell proliferation, activity, and growth. This blocks the activity that leads to the growth of the B-cells and causes cell death of the malignant B-cells. Jaypirca belongs to the class of drugs called Bruton's tyrosine kinase (BTK) inhibitors and is highly selective for BTK (300 times more selective than most other kinases).
Pirtobrutinib FDA approval is for adult patients with:
Common pirtobrutinib side effects may include bruising, tiredness, diarrhea, swelling, muscle, joint pain, bone pain, fever, chills, cough with mucus, chest pain, and feeling short of breath.
Get emergency medical help if you have signs of an allergic reaction, such as hives, difficulty breathing, or swelling of your face, lips, tongue, or throat.
Other serious pirtobrutinib side effects. Call your doctor at once if you have:
印度肿瘤药房(India Pharmacy)是印度新德里肿瘤药房信息咨询服务平台,旨在为患者提供各类进口原研 进口仿制 最新研制等医药信息咨询 跨境医药电商直邮服务,让患者轻松获取全球最佳药品有更多选择,基本涵盖新特药 抗癌药 靶向药 丙肝 乙肝 高血压 糖尿病 痛风 等药品,欢迎咨询!官方微信 Yindu7689